Neuren Pharmaceuticals Limited
NURPF
$10.97
-$1.31-10.67%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -9.49% | 21.75% | 106.31% | 381.96% | 47,103.63% |
| Total Depreciation and Amortization | 28.32% | 49.48% | 75.61% | 68.42% | 63.77% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 77.30% | 54.42% | 7.49% | 31.60% | 52.54% |
| Change in Net Operating Assets | -806.00% | -939.43% | 76.02% | 876.27% | 3,991.92% |
| Cash from Operations | -106.07% | -55.57% | 112.79% | 409.48% | 5,617.61% |
| Capital Expenditure | 75.19% | 48.66% | 10.38% | -34.59% | -100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 101.97% | 39.52% | -233.88% | -659.63% | -- |
| Cash from Investing | 101.96% | 39.52% | -233.74% | -659.02% | -1,046,657.14% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -54.36% | 23.45% | 279.80% | 609.24% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 50.00% | -16.00% | -185.71% | -322.22% | -800.00% |
| Cash from Financing | -342.93% | -201.10% | 268.87% | 583.27% | 170,728.57% |
| Foreign Exchange rate Adjustments | 1,330.16% | 710.17% | 583.02% | 477.11% | 8.61% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 39.32% | -213.99% | -580.16% | -658.74% | -855.74% |